-
June 30, 2021 Lupin Receives Tentative U.S. FDA Approval for Dolutegravir, Lamivudine and Tenofovir Disoproxil Fumarate (TLD) Tablets under PEPFAR
-
June 25, 2021 Lupin Launches Emtricitabine and Tenofovir Disoproxil Fumarate Tablets in the United States
-
June 17, 2021 Lupin Receives U.S. FDA Approval for Sevelamer Hydrochloride Tablets
-
June 14, 2021 Lupin receives UK marketing authorization for Luforbec® 100/6 µg pMDI, first branded generic alternative to Fostair® 100/6 µg pMDI for treatment of Asthma & COPD
-
June 11, 2021 Lupin donates Oxygen generation plants in Maharashtra, Madhya Pradesh & Gujarat to aid COVID-19 relief efforts
-
June 3, 2021 Lupin Launches Authorized Generic Version of Brovana® in the United States
-
June 2, 2021 Lupin announces U.S. FDA acceptance for Pegfilgrastim Biosimilar application
-
May 27, 2021 Lupin Announces Achievement of Key Milestones for its Clinical Stage MEK Inhibitor Compound
-
May 13, 2021 Lupin Q4 FY2021 Results
In this section
Media Contacts
-
Rajalakshmi Azariah
Vice President & Global Head – Corporate Communications